ReviewJournal of diabetes and metabolic disorders2019
Patient and physician preferences for type 2 diabetes medications: a systematic review.
Review in Journal of diabetes and metabolic disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Patients' and informal caregivers' perspectives on self-management interventions for type 2 diabetes mellitus outcomes: a mixed-methods overview of 14 years of reviews.Archives of public health = Archives belges de sante publique · 2023Pooled it
- Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.Nature medicine · 2023Trial
- Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.Diabetes, obesity & metabolism · 2021Trial
- A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide.Endocrine · 2020Trial
- Deprescribing Following Access to Lifestyle Treatment: A Retrospective Chart Review of Primary Care Outcomes in Patients with Type 2 Diabetes.Journal of clinical medicine · 2026Article
- Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Quantifying Patient Preferences for Basal Insulin Treatments in Adults Living with Type 2 Diabetes: A Discrete Choice Experiment in Canada, Spain, France, and Japan.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Treatment Preferences for Novel Type 2 Diabetes Oral Medications: Insights from the Asian Diabetes Patient Preference Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults: A Clinical Practice Guideline From the American College of Lifestyle Medicine.American journal of lifestyle medicine · 2025Article
- Perspectives of People with Type 2 Diabetes Mellitus Towards a Decision Aid Assessing Preferences of Glucose-Lowering Drugs: The Dilemma of Choosing.Patient preference and adherence · 2025Article
- Understanding the struggle: Unique challenges of adherence in male diabetic patients in Tshwane.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2024Article
- Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey.BMJ global health · 2023Article
- Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.Journal of managed care & specialty pharmacy · 2023Review
- Preferred Conversation Topics with Respect to Treatment Decisions Among Individuals with Type 2 Diabetes.Patient preference and adherence · 2023Article
- Methods to Summarize Discrete-Choice Experiments in a Systematic Review: A Scoping Review.The patient · 2022Article
- Patient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment.Journal of diabetes and metabolic disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are several treatments to cure type 2 diabetes (T2D) and every one of them has certain attributes which is lead patients and specialists to have different preferences and select power. Therefore, we did this systematic study to evaluate patients̓ and physicians̓ preferences for type 2 diabetes medications by extracting attributes of anti-diabetic medications and identifying their relative importance.
methodsWe searched the PubMed, Ovid, Web of science, Scopus and Embase databases for articles which have been published on or before May 8th, 2018(The start time of the search in our study was May 8th, 2018).
resultsThe searches identified 3346 studies, of which 17 (from 2009 to 2017) were included in the final synthesis and 27 attributes of type 2 anti-diabetic have been investigated. The most important attributes are changes of blood glucose and HbA1c level, hypoglycemia events, weight changes, gastrointestinal complications, cardiovascular effects, medicines cost, and administration mode and dosage of medicines.
conclusionphysicians and patients prefer antidiabetics which is reduce blood glucose and HbA1c level effectively and have low side effects too (hypoglycemic event, cardiovascular and gastrointestinal). The effect of weight reduction, low cost, low dosing and low frequency of using. Health care providers, Specialist, and manufacturers should consider to these attributes in treatment process and marketing. It can increase adherence to management approaches, and reduce morbidity of patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.